** Medical equipment maker Revvity's RVTY.N shares rise 8.2% to $102 premarket
** RVTY posts Q1 profit and revenue above Wall Street estimates and maintains its full-year profit forecast, helped by steady demand from biotech clients for medical equipment used for drug research
** Company posts a Q1 adj. profit of $1.01 per share, above analysts' estimates of 95 cents, according to data compiled by LSEG
** It reported Q1 revenue of $664.8 million, slightly above estimates of $661.2 million
** Company maintains annual profit forecast of $4.90 to $5 per share on an adjusted basis
** RVTY now sees 2025 revenue to be between $2.83 billion and $2.87 billion, compared with the previous projection of $2.80 billion to $2.85 billion
** Up to last close, stock had fallen 15.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。